2 documents found, page 1 of 1
Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disea...
Yoo, SGK; Chung, GS; Bahendeka, SK; Sibai, AM; Damasceno, A; Farzadfar, F; Rohloff, P; Houehanou, C; Norov, B; Karki, KB; Azangoukhyavy, M; Marcus, METhe role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant th...
Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-,...
Yoo, SGK; Chung, GS; Bahendeka, SK; Sibai, AM; Damasceno, A; Farzadfar, F; Rohloff, P; Houehanou, C; Norov, B; Karki, KB; Azangou-Khyavy, M; Marcus, ME"Importance Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. Objective To report and evaluate aspirin use for secondary prevention of CVD a...